Home » Stocks » TTNP

Titan Pharmaceuticals, Inc. (TTNP)

Stock Price: $3.31 USD -0.03 (-0.90%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $3.38 +0.07 (2.12%) Feb 26, 7:56 PM
Market Cap 32.45M
Revenue (ttm) 5.00M
Net Income (ttm) -19.10M
Shares Out 3.26M
EPS (ttm) -7.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $3.31
Previous Close $3.34
Change ($) -0.03
Change (%) -0.90%
Day's Open 3.34
Day's Range 3.10 - 3.42
Day's Volume 1,166,861
52-Week Range 2.82 - 16.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated h...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredite...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-fo...

Pulse2 - 3 months ago

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended Se...

InvestorPlace - 3 months ago

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

Other stocks mentioned: CIDM, DVAX, NEOS, NOK, RYCEY, WTRH
PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a pr...

InvestorPlace - 3 months ago

Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Inves...

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases...

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders a...

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Seeking Alpha - 6 months ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its c...

PRNewsWire - 8 months ago

SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Inde...

Seeking Alpha - 9 months ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended Mar...

Investopedia - 10 months ago

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: ALIM, CPIX, OSG, RRTS
Seeking Alpha - 10 months ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP) will release its latest earnings report.

Seeking Alpha - 1 year ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2018 Results - Earnings Call Transcript

About TTNP

Titan Pharmaceuticals, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based i... [Read more...]

Industry
Biotechnology
IPO Date
Jan 18, 1996
Stock Exchange
NASDAQ
Ticker Symbol
TTNP
Full Company Profile

Financial Performance

In 2019, TTNP's revenue was $3.61 million, a decrease of -45.44% compared to the previous year's $6.62 million. Losses were -$16.46 million, 82.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 11.00.

Price Target
$11.00
Analyst Consensus: Buy